The Involvement of Glucose and Lipid Metabolism Alteration in Rheumatoid Arthritis and Its Clinical Implication

References

• Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nat Immunol. 2021;22(1):10–18.
   PubMed Web of Science ®Google Scholar
• Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):110.
   PubMedGoogle Scholar
• Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review. Eur J Med Chem. 2018;158:502–516.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Atsumi T, Tanaka Y, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (Surprise study). Ann Rheum Dis. 2016;75(11):1917–1923.
   PubMed Web of Science ®Google Scholar
• Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with Abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74(1):19–26.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016;75(6):1081–1091.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and Adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390(10093):457–468.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr. et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Panoulas V, Kitas GD. Pharmacological management of cardiovascular risk in chronic inflammatory rheumatic diseases. Expert Rev Clin Pharmacol. 2020;13(6):605–613.
   PubMed Web of Science ®Google Scholar
• Mehta S, Farmer JA. Obesity and inflammation: a new look at an old problem. Curr Atheroscler Rep. 2007;9(2):134–138.
   PubMedGoogle Scholar
• Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, et al. Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis. 2009;68(2):242–245.
   PubMedGoogle Scholar
• Ali L, Schnitzler JG, Kroon J. Metabolism: the road to inflammation and atherosclerosis. Curr Opin Lipidol. 2018;29(6):474–480.
   PubMedGoogle Scholar
• Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55(1):31–55.
   PubMed Web of Science ®Google Scholar
• Chung CP, Oeser A, Solus JF, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis. 2008;196(2):756–763.
   PubMed Web of Science ®Google Scholar
• Young SP, Kapoor SR, Viant MR, et al. The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheum. 2013;65(8):2015–2023.
   PubMedGoogle Scholar
• Nicolau J, Lequerre T, Bacquet H, Vittecoq O. Rheumatoid arthritis, insulin resistance, and diabetes. Joint Bone Spine. 2017;84(4):411–416.
   PubMedGoogle Scholar
• Pucino V, Certo M, Varricchi G, et al. Metabolic checkpoints in rheumatoid arthritis. Front Physiol. 2020;11:347.
   PubMed Web of Science ®Google Scholar
• Judge A, Dodd Michael S. Metabolism. Essays Biochem. 2020;64(4):607–647.
   PubMedGoogle Scholar
• Kim EK, Kwon JE, Lee SY, et al. IL-17-mediated mitochondrial dysfunction impairs apoptosis in rheumatoid arthritis synovial fibroblasts through activation of autophagy. Cell Death Dis. 2017;8(1):e2565.
   PubMed Web of Science ®Google Scholar
• Alissafi T, Kalafati L, Lazari M, et al. Mitochondrial oxidative damage underlies regulatory T cell defects in autoimmunity. Cell Metab. 2020;32(4):591–604e597.
   PubMedGoogle Scholar
• Wu B, Qiu J, Zhao TV, et al. Succinyl-CoA ligase deficiency in pro-inflammatory and tissue-invasive T cells. Cell Metab. 2020;32(6):967–980.
   PubMedGoogle Scholar
• Weyand CM, Fujii H, Shao L, Goronzy JJ. Rejuvenating the immune system in rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10):583–588.
   PubMed Web of Science ®Google Scholar
• Goronzy JJ, Weyand CM. Aging, autoimmunity and arthritis: t-cell senescence and contraction of T-cell repertoire diversity - catalysts of autoimmunity and chronic inflammation. Arthritis Res Ther. 2003;5(5):225–234.
   PubMedGoogle Scholar
• Koetz K, Bryl E, Spickschen K, O’Fallon WM, Goronzy JJ, Weyand CM. Cell homeostasis in patients with rheumatoid arthritis. P Natl Acad Sci USA. 2000;97(16):9203–9208.
   PubMed Web of Science ®Google Scholar
• Li Y, Shen Y, Jin K, et al. The DNA repair nuclease MRE11A functions as a mitochondrial protector and prevents T cell pyroptosis and tissue inflammation. Cell Metab. 2019;30(3):477–492.
   PubMedGoogle Scholar
• Li Y, Shen Y, Hohensinner P, et al. Deficient activity of the nuclease MRE11A induces T cell aging and promotes arthritogenic effector functions in patients with rheumatoid arthritis. Immunity. 2016;45(4):903–916.
   PubMedGoogle Scholar
• Syed A, Tainer JA. The MRE11-RAD50-NBS1 complex conducts the orchestration of damage signaling and outcomes to stress in DNA replication and repair. Annu Rev Biochem. 2018;87:263–294.
   PubMed Web of Science ®Google Scholar
• Panga V, Kallor AA, Nair A, Harshan S, Raghunathan S. Mitochondrial dysfunction in rheumatoid arthritis: a comprehensive analysis by integrating gene expression, protein-protein interactions and gene ontology data. PLoS One. 2019;14(11):e0224632.
   PubMed Web of Science ®Google Scholar
• Khanna S, Padhan P, Jaiswal KS, et al. Altered mitochondrial proteome and functional dynamics in patients with rheumatoid arthritis. Mitochondrion. 2020;54:8–14.
   PubMed Web of Science ®Google Scholar
• Zeisbrich M, Yanes RE, Zhang H, et al. Hypermetabolic macrophages in rheumatoid arthritis and coronary artery disease due to glycogen synthase kinase 3b inactivation. Ann Rheum Dis. 2018;77(7):1053–1062.
   PubMed Web of Science ®Google Scholar
• Lopez-Armada MJ, Fernandez-Rodriguez JA, Blanco FJ. Mitochondrial dysfunction and oxidative stress in rheumatoid arthritis. Antioxidants. 2022;11:6.
   Google Scholar
• Ferraz-Amaro I, Gonzalez-Juanatey C, Lopez-Mejias R, Riancho-Zarrabeitia L, Gonzalez-Gay MA. Metabolic syndrome in rheumatoid arthritis. Mediators Inflamm. 2013;2013:710928.
   PubMed Web of Science ®Google Scholar
• Miesel R, Murphy MP, Kröger H. Enhanced mitochondrial radical production in patients with rheumatoid arthritis correlates with elevated levels of tumor necrosis factor alpha in plasma. Free Radic Res. 1996;25(2):161–169.
   PubMed Web of Science ®Google Scholar
• Kundu S, Ghosh P, Datta S, Ghosh A, Chattopadhyay S, Chatterjee M. Oxidative stress as a potential biomarker for determining disease activity in patients with rheumatoid arthritis. Free Radic Res. 2012;46(12):1482–1489.
   PubMed Web of Science ®Google Scholar
• Kundu S, Bala A, Ghosh P, et al. Attenuation of oxidative stress by allylpyrocatechol in synovial cellular infiltrate of patients with rheumatoid arthritis. Free Radic Res. 2011;45(5):518–526.
   PubMed Web of Science ®Google Scholar
• Biniecka M, Kennedy A, Fearon U, Ng CT, Veale DJ, O’Sullivan JN. Oxidative damage in synovial tissue is associated with in vivo hypoxic status in the arthritic joint. Ann Rheum Dis. 2010;69(6):1172–1178.
   PubMed Web of Science ®Google Scholar
• Smallwood MJ, Nissim A, Knight AR, Whiteman M, Haigh R, Winyard PG. Oxidative stress in autoimmune rheumatic diseases. Free Radic Biol Med. 2018;125:3–14.
   PubMed Web of Science ®Google Scholar
• Hargreaves M, Spriet LL. Exercise metabolism: fuels for the fire. Cold Spring Harb Perspect Med. 2018;8:8.
   Google Scholar
• Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative stress in cancer. Cancer Cell. 2020;38(2):167–197.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonell R, Divakaruni AS, Lodi A, et al. Critical role of glucose metabolism in rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Rheumatol. 2016;68(7):1614–1626.
   PubMed Web of Science ®Google Scholar
• Rennie KL, Hughes J, Lang R, Jebb SA. Nutritional management of rheumatoid arthritis: a review of the evidence. J Hum Nutr Diet. 2003;16(2):97–109.
   PubMedGoogle Scholar
• Masoumi M, Mehrabzadeh M, Mahmoudzehi S, et al. Role of glucose metabolism in aggressive phenotype of fibroblast-like synoviocytes: latest evidence and therapeutic approaches in rheumatoid arthritis. Int Immunopharmacol. 2020;89(Pt A):107064.
   PubMedGoogle Scholar
• Petrasca A, Phelan JJ, Ansboro S, Veale DJ, Fearon U, Fletcher JM. Targeting bioenergetics prevents CD4 T cell–mediated activation of synovial fibroblasts in rheumatoid arthritis. Rheumatology. 2020;59(10):2816–2828.
   PubMedGoogle Scholar
• Henderson B, Bitensky L, Chayen J. Glycolytic activity in human synovial lining cells in rheumatoid arthritis. Ann Rheum Dis. 1979;38(1):63–67.
   PubMedGoogle Scholar
• Hakala M, Kroger H, Valleala H, et al. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial. Scand J Rheumatol. 2012;41(4):260–266.
   PubMed Web of Science ®Google Scholar
• Tan VP, Miyamoto S. HK2/hexokinase-II integrates glycolysis and autophagy to confer cellular protection. Autophagy. 2015;11(6):963–964.
   PubMed Web of Science ®Google Scholar
• Bustamante MF, Oliveira PG, Garcia-Carbonell R, et al. Hexokinase 2 as a novel selective metabolic target for rheumatoid arthritis. Ann Rheum Dis. 2018;77(11):1636–1643.
   PubMed Web of Science ®Google Scholar
• Song G, Lu Q, Fan H, et al. Inhibition of hexokinases holds potential as treatment strategy for rheumatoid arthritis. Arthritis Res Ther. 2019;21:1.
   PubMedGoogle Scholar
• Temre MK, Kumar A, Singh SM. An appraisal of the current status of inhibition of glucose transporters as an emerging antineoplastic approach: promising potential of new pan-GLUT inhibitors. Front Pharmacol. 2022;13:1035510.
   PubMedGoogle Scholar
• Simpfendorfer KR, Li W, Shih A, et al. Influence of genetic copy number variants of the human GLUT3 glucose transporter gene SLC2A3 on protein expression, glycolysis and rheumatoid arthritis risk: a genetic replication study. Mol Genet Metab Rep. 2019;19:100470.
   PubMedGoogle Scholar
• de Oliveira PG, Farinon M, Sanchez-Lopez E, Miyamoto S, Guma M. Fibroblast-like synoviocytes glucose metabolism as a therapeutic target in rheumatoid arthritis. Front Immunol. 2019;10:1743.
   PubMed Web of Science ®Google Scholar
• Hua S, Dias TH. Hypoxia-Inducible Factor (HIF) as a target for novel therapies in rheumatoid arthritis. Front Pharmacol. 2016;7:184.
   PubMed Web of Science ®Google Scholar
• Hu F, Liu H, Xu L, et al. Hypoxia-inducible factor-1alpha perpetuates synovial fibroblast interactions with T cells and B cells in rheumatoid arthritis. Eur J Immunol. 2016;46(3):742–751.
   PubMed Web of Science ®Google Scholar
• Hu F, Mu R, Zhu J, et al. Hypoxia and hypoxia-inducible factor-1alpha provoke toll-like receptor signalling-induced inflammation in rheumatoid arthritis. Ann Rheum Dis. 2014;73(5):928–936.
   PubMed Web of Science ®Google Scholar
• Kierans SJ, Taylor CT. Regulation of glycolysis by the hypoxia-inducible factor (HIF): implications for cellular physiology. J Physiol. 2021;599(1):23–37.
   PubMed Web of Science ®Google Scholar
• Shi LZ, Wang R, Huang G, et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med. 2011;208(7):1367–1376.
   PubMed Web of Science ®Google Scholar
• Goronzy JJ, Weyand CM. Mechanisms underlying T cell ageing. Nat Rev Immunol. 2019;19(9):573–583.
   PubMed Web of Science ®Google Scholar
• Vignali PDA, Barbi J, Pan F. Metabolic regulation of T cell immunity. Adv Exp Med Biol. 2017;1011:87–130.
   PubMedGoogle Scholar
• Samuelson BT, Vesely SK, Chai-Adisaksopha C, Scott BL, Crowther M, Garcia D. The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. Blood Coagul Fibrinolysis. 2016;27(6):648–652.
   PubMed Web of Science ®Google Scholar
• Kerekes G, Nurmohamed MT, Gonzalez-Gay MA, et al. Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol. 2014;10(11):691–696.
   PubMed Web of Science ®Google Scholar
• Pi H, Zhou H, Jin H, Ning Y, Wang Y. Abnormal glucose metabolism in rheumatoid arthritis. Biomed Res Int. 2017;2017:9670434.
   PubMedGoogle Scholar
• Yang Z, Fujii H, Mohan SV, Goronzy JJ, Weyand CM. Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells. J Exp Med. 2013;210(10):2119–2134.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Shen Y, Goronzy JJ. Redox-sensitive signaling in inflammatory T cells and in autoimmune disease. Free Radic Biol Med. 2018;125:36–43.
   PubMed Web of Science ®Google Scholar
• Bartrons R, Rodriguez-Garcia A, Simon-Molas H, Castano E, Manzano A, Navarro-Sabate A. The potential utility of PFKFB3 as a therapeutic target. Expert Opin Ther Targets. 2018;22(8):659–674.
   PubMed Web of Science ®Google Scholar
• Yalcin A, Telang S, Clem B, Chesney J. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in cancer. Exp Mol Pathol. 2009;86(3):174–179.
   PubMed Web of Science ®Google Scholar
• Yang Z, Shen Y, Oishi H, et al. Restoring oxidant signaling suppresses proarthritogenic T cell effector functions in rheumatoid arthritis. Sci Transl Med. 2016;8(331):331ra338–331ra338.
   Google Scholar
• Weyand CM, Goronzy JJ. Immunometabolism in the development of rheumatoid arthritis. Immunol Rev. 2020;294(1):177–187.
   PubMed Web of Science ®Google Scholar
• Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol. 2017;27(21):R1147–R1151.
   PubMed Web of Science ®Google Scholar
• Yang HC, Wu YH, Liu HY, Stern A, Chiu DT. What has passed is prolog: new cellular and physiological roles of G6PD. Free Radic Res. 2016;50(10):1047–1064.
   PubMed Web of Science ®Google Scholar
• Senolt L, Pavelka K, Housa D, Haluzik M. Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine. 2006;35(5–6):247–252.
   PubMedGoogle Scholar
• Mittler R. ROS are good. Trends Plant Sci. 2017;22(1):11–19.
   PubMed Web of Science ®Google Scholar
• Jones JG. Hepatic glucose and lipid metabolism. Diabetologia. 2016;59(6):1098–1103.
   PubMed Web of Science ®Google Scholar
• Olzmann JA, Carvalho P. Dynamics and functions of lipid droplets. Nat Rev Mol Cell Biol. 2019;20(3):137–155.
   PubMed Web of Science ®Google Scholar
• Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325–331.
   PubMed Web of Science ®Google Scholar
• Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690–1697.
   PubMed Web of Science ®Google Scholar
• van den Oever IA, van Sijl AM, Nurmohamed MT. Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion. Ther Adv Musculoskelet Dis. 2013;5(4):166–181.
   PubMedGoogle Scholar
• Giles JT, Allison M, Blumenthal RS, et al. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum. 2010;62(11):3173–3182.
   PubMedGoogle Scholar
• Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62–68.
   PubMed Web of Science ®Google Scholar
• Kruger K, Nusslein H. Kardiovaskuläre Komorbiditäten bei rheumatoider Arthritis[Cardiovascular comorbidities in rheumatoid arthritis]. Z Rheumatol. 2019;78(3):221–227. German.
   PubMedGoogle Scholar
• Erum U, Ahsan T, Khowaja D. Lipid abnormalities in patients with rheumatoid arthritis. Pak J Med Sci. 2017;33:1.
   PubMedGoogle Scholar
• Lazarevic MB, Vitic J, Mladenovic V, Myones BL, Skosey JL, Swedler WI. Dyslipoproteinemia in the course of active rheumatoid arthritis. Nat Libr Med. 1992;22(3):172–178.
   Google Scholar
• Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70(3):482–487.
   PubMed Web of Science ®Google Scholar
• Liao KP, Playford MP, Frits M, et al. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc. 2015;4:2.
   Google Scholar
• Zhang J, Chen L, Delzell E, et al. The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis. 2014;73(7):1301–1308.
   PubMedGoogle Scholar
• Charles-Schoeman C, Watanabe J, Lee YY, et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum. 2009;60(10):2870–2879.
   PubMedGoogle Scholar
• Charles-Schoeman C, Lee YY, Grijalva V, et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis. 2012;71(7):1157–1162.
   PubMed Web of Science ®Google Scholar
• Hashizume M, Mihara M. Atherogenic effects of TNF-alpha and IL-6 via up-regulation of scavenger receptors. Cytokine. 2012;58(3):424–430.
   PubMed Web of Science ®Google Scholar
• Lubrano V, Gabriele M, Puntoni MR, Longo V, Pucci L. Relationship among IL-6, LDL cholesterol and lipid peroxidation. Cell Mol Biol Lett. 2015;20(2):310–322.
   PubMedGoogle Scholar
• Charles-Schoeman C, Fleischmann R, Davignon J, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol. 2015;67(3):616–625.
   PubMed Web of Science ®Google Scholar
• Robertson J, Porter D, Sattar N, et al. Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Ann Rheum Dis. 2017;76(11):1949–1952.
   PubMedGoogle Scholar
• Weyand CM, Wu B, Goronzy JJ. The metabolic signature of T cells in rheumatoid arthritis. Curr Opin Rheumatol. 2020;32(2):159–167.
   PubMedGoogle Scholar
• Chang M, Hamilton JA, Scholz GM, Elsegood CL. Glycolytic control of adjuvant-induced macrophage survival: role of PI3K, MEK1/2, and Bcl-2. J Leukoc Biol. 2009;85(6):947–956.
   PubMedGoogle Scholar
• Cheng SC, Quintin J, Cramer RA, et al. mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014;345(6204):1250684.
   PubMed Web of Science ®Google Scholar
• Krawczyk CM, Holowka T, Sun J, et al. Toll-like receptor–induced changes in glycolytic metabolism regulate dendritic cell activation. Blood. 2010;115(23):4742–4749.
   PubMed Web of Science ®Google Scholar
• Siska PJ, Rathmell JC. T cell metabolic fitness in antitumor immunity. Trends Immunol. 2015;36(4):257–264.
   PubMed Web of Science ®Google Scholar
• Inkster B, Zai G, Lewis G, Miskowiak KW. GSK3beta: a plausible mechanism of cognitive and hippocampal changes induced by erythropoietin treatment in mood disorders? Transl Psychiatry. 2018;8(1):216.
   PubMedGoogle Scholar
• van der Vaart A, Meng X, Bowers MS, et al. Glycogen synthase kinase 3 beta regulates ethanol consumption and is a risk factor for alcohol dependence. Neuropsychopharmacology. 2018;43(13):2521–2531.
   PubMedGoogle Scholar
• Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J. 2001;59(1):1–16.
   Google Scholar
• Sopjani M, Millaku L, Nebija D, Emini M, Rifati-Nixha A, Dermaku-Sopjani M. The glycogen synthase kinase-3 in the regulation of ion channels and cellular carriers. Curr Med Chem. 2019;26(37):6817–6829.
   PubMedGoogle Scholar
• Sarbassov DD, Guertin DA, Ali SM, Sabatini DMJS. Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR complex. Science. 2005;307(5712):1098–1101.
   PubMed Web of Science ®Google Scholar
• Ben-Sahra I, Howell JJ, Asara JM, Manning BD. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science. 2013;339(6125):1323–1328.
   PubMed Web of Science ®Google Scholar
• Maiese K, Chong ZZ, Shang YC, Wang S. mTOR: on target for novel therapeutic strategies in the nervous system. Trends Mol Med. 2013;19(1):51–60.
   PubMed Web of Science ®Google Scholar
• Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2):85–95.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721–732.
   PubMed Web of Science ®Google Scholar
• Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21(3):297–308.
   PubMed Web of Science ®Google Scholar
• Li W, Wang K, Liu Y, et al. A novel drug combination of mangiferin and cinnamic acid alleviates rheumatoid arthritis by inhibiting TLR4/NFkappaB/NLRP3 activation-induced pyroptosis. Front Immunol. 2022;13:912933.
   PubMedGoogle Scholar
• Liu S, Ma H, Zhang H, Deng C, Xin P. Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis. Clin Immunol. 2021;230:108793.
   PubMed Web of Science ®Google Scholar
• Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19(2):121–135.
   PubMed Web of Science ®Google Scholar
• Weyand CM, Goronzy JJ. Immunometabolism in early and late stages of rheumatoid arthritis. Nat Rev Rheumatol. 2017;13(5):291–301.
   PubMedGoogle Scholar
• Toyama EQ, Herzig S, Courchet J, et al. Metabolism. AMP-activated protein kinase mediates mitochondrial fission in response to energy stress. Science. 2016;351(6270):275–281.
   PubMed Web of Science ®Google Scholar
• Zong H, Ren JM, Young LH, et al. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci. 2002;99(25):5983–5987.
   Google Scholar
• Jäger S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci. 2007;104(29):12017–12022.
   PubMed Web of Science ®Google Scholar
• Egan DF, Shackelford DB, Mihaylova MM, et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science. 2011;331(6016):456–461.
   PubMed Web of Science ®Google Scholar
• Carling D, Zammit VA, Hardie DG. A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett. 1987;223(2):217–222.
   PubMed Web of Science ®Google Scholar
• Munday MR, Campbell DG, Carling D, Hardie DG. Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. Eur J Biochem. 1988;175(2):331–338.
   PubMedGoogle Scholar
• Watt MJ, Holmes AG, Pinnamaneni SK, et al. Regulation of HSL serine phosphorylation in skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab. 2006;290(3):E500–508.
   PubMed Web of Science ®Google Scholar
• Marsin AS, Bertrand L, Rider MH, et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol. 2000;10(20):1247–1255.
   PubMed Web of Science ®Google Scholar
• Bando H, Atsumi T, Nishio T, et al. Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer. Clin Cancer Res. 2005;11(16):5784–5792.
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Holman GD. Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of GLUT4 traffic. Am J Physiol Endocrinol Metab. 2008;295(1):E29–37.
   PubMedGoogle Scholar
• Wu N, Zheng B, Shaywitz A, et al. AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol Cell. 2013;49(6):1167–1175.
   PubMedGoogle Scholar
• Zhang C-S, Jiang B, Li M, et al. The lysosomal v-ATPase-ragulator complex is a common activator for AMPK and mTORC1, acting as a switch between catabolism and anabolism. Cell Metab. 2014;20(3):526–540.
   PubMed Web of Science ®Google Scholar
• Liang J, Xu ZX, Ding Z, et al. Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance. Nat Commun. 2015;6:7926.
   PubMed Web of Science ®Google Scholar
• Oakhill JS, Chen ZP, Scott JW, et al. beta-Subunit myristoylation is the gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK). Proc Natl Acad Sci USA. 2010;107(45):19237–19241.
   PubMed Web of Science ®Google Scholar
• Wen Z, Jin K, Shen Y, et al. N-myristoyltransferase deficiency impairs activation of kinase AMPK and promotes synovial tissue inflammation. Nat Immunol. 2019;20(3):313–325.
   PubMed Web of Science ®Google Scholar
• Canto C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458(7241):1056–1060.
   PubMed Web of Science ®Google Scholar
• Pernicova I, Kelly S, Ajodha S, et al. Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, Phase 2 trial. Lancet Diabetes Endocrinol. 2020;8(4):278–291.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Davis RJ. Cell signaling and stress responses. Cold Spring Harb Perspect Biol. 2016;8(10):5.
   Google Scholar
• Kauppinen A, Suuronen T, Ojala J, Kaarniranta K, Salminen A. Antagonistic crosstalk between NF-kappaB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal. 2013;25(10):1939–1948.
   PubMed Web of Science ®Google Scholar
• Nakano R, Nakayama T, Sugiya H. Biological properties of JNK3 and its function in neurons, astrocytes, pancreatic beta-cells and cardiovascular cells. Cells. 2020;9:8.
   Google Scholar
• Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature. 2002;420(6913):333–336.
   PubMed Web of Science ®Google Scholar
• Becattini B, Zani F, Breasson L, et al. JNK1 ablation in mice confers long-term metabolic protection from diet-induced obesity at the cost of moderate skin oxidative damage. FASEB J. 2016;30(9):3124–3132.
   PubMed Web of Science ®Google Scholar
• Yu XX, Murray SF, Watts L, et al. Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice. Am J Physiol Endocrinol Metab. 2008;295(2):E436–445.
   PubMedGoogle Scholar
• Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996;271(5249):665–668.
   PubMed Web of Science ®Google Scholar
• Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem. 2000;275(12):9047–9054.
   PubMed Web of Science ®Google Scholar
• Sabio G, Cavanagh-Kyros J, Ko HJ, et al. Prevention of steatosis by hepatic JNK1. Cell Metab. 2009;10(6):491–498.
   PubMedGoogle Scholar
• Kang T, Huang H, Mandrup-Poulsen T, Larsen MR. Divalent metal transporter 1 knock-down modulates IL-1beta mediated pancreatic beta-cell pro-apoptotic signaling pathways through the autophagic machinery. Int J Mol Sci. 2021;22:15.
   Google Scholar
• Aye IL, Jansson T, Powell TL. Interleukin-1beta inhibits insulin signaling and prevents insulin-stimulated system A amino acid transport in primary human trophoblasts. Mol Cell Endocrinol. 2013;381(1–2):46–55.
   PubMed Web of Science ®Google Scholar
• Copps KD, White MF. Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia. 2012;55(10):2565–2582.
   PubMed Web of Science ®Google Scholar
• Liu C, Feng X, Li Q, Wang Y, Li Q, Hua M. Adiponectin, TNF-alpha and inflammatory cytokines and risk of type 2 diabetes: a systematic review and meta-analysis. Cytokine. 2016;86:100–109.
   PubMed Web of Science ®Google Scholar
• Liang Y, Xu WD, Peng H, Pan HF, Ye DQ. SOCS signaling in autoimmune diseases: molecular mechanisms and therapeutic implications. Eur J Immunol. 2014;44(5):1265–1275.
   PubMed Web of Science ®Google Scholar
• Whitham M, Pal M, Petzold T, et al. Adipocyte-specific deletion of IL-6 does not attenuate obesity-induced weight gain or glucose intolerance in mice. Am J Physiol Endocrinol Metab. 2019;317(4):E597–E604.
   PubMed Web of Science ®Google Scholar
• Han MS, White A, Perry RJ, et al. Regulation of adipose tissue inflammation by interleukin 6. Proc Natl Acad Sci USA. 2020;117(6):2751–2760.
   PubMedGoogle Scholar
• Runtuwene J, Cheng KC, Asakawa A, et al. Rosmarinic acid ameliorates hyperglycemia and insulin sensitivity in diabetic rats, potentially by modulating the expression of PEPCK and GLUT4. Drug Des Devel Ther. 2016;10:2193–2202.
   PubMed Web of Science ®Google Scholar
• Umar S, Palasiewicz K, Volin MV, et al. Metabolic regulation of RA macrophages is distinct from RA fibroblasts and blockade of glycolysis alleviates inflammatory phenotype in both cell types. Cell Mol Life Sci. 2021;78(23):7693–7707.
   PubMedGoogle Scholar
• Kononoff A, Vuolteenaho K, Hamalainen M, et al. Metabolic syndrome, disease activity, and adipokines in patients with newly diagnosed inflammatory joint diseases. J Clin Rheumatol. 2021;27(8):e349–e356.
   PubMedGoogle Scholar
• Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab. 2016;23(5):770–784.
   PubMed Web of Science ®Google Scholar
• Obradovic M, Sudar-Milovanovic E, Soskic S, et al. Leptin and obesity: role and clinical implication. Front Endocrinol. 2021;12:585887.
   PubMed Web of Science ®Google Scholar
• Paquet J, Goebel JC, Delaunay C, et al. Cytokines profiling by multiplex analysis in experimental arthritis: which pathophysiological relevance for articular versus systemic mediators? Arthritis Res Ther. 2012;14(2):R60.
   PubMedGoogle Scholar
• Tian G, Liang JN, Pan HF, Zhou D. Increased leptin levels in patients with rheumatoid arthritis: a meta-analysis. Ir J Med Sci. 2014;183(4):659–666.
   PubMed Web of Science ®Google Scholar
• Sugioka Y, Tada M, Okano T, et al. Acquired leptin resistance by high-fat feeding reduces inflammation from collagen antibody-induced arthritis in mice. Clin Exp Rheumatol. 2012;30:5.
   Google Scholar
• Bastard J-P, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4–12.
   PubMed Web of Science ®Google Scholar
• Shervington L, Darekar A, Shaikh M, Mathews R, Shervington A. Identifying reliable diagnostic/predictive biomarkers for rheumatoid arthritis. Biomark Insights. 2018;13:1177271918801005.
   Google Scholar
• Boers M, Nurmohamed MT, Doelman CJA, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62(9):842–845.
   PubMed Web of Science ®Google Scholar
• Georgiadis AN, Papavasiliou EC, Lourida ES, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study. Arthritis Res Ther. 2006;8(3):R82.
   PubMed Web of Science ®Google Scholar
• Morris SJ, Wasko MC, Antohe JL, et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res. 2011;63(4):530–534.
   Google Scholar
• Biniecka M, Canavan M, McGarry T, et al. Dysregulated bioenergetics: a key regulator of joint inflammation. Ann Rheum Dis. 2016;75(12):2192–2200.
   PubMed Web of Science ®Google Scholar
• Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480–489.
   PubMed Web of Science ®Google Scholar
• Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(4):576–582.
   PubMed Web of Science ®Google Scholar
• McGarry T, Orr C, Wade S, et al. JAK/STAT blockade alters synovial bioenergetics, mitochondrial function, and proinflammatory mediators in rheumatoid arthritis. Arthritis Rheumatol. 2018;70(12):1959–1970.
   PubMed Web of Science ®Google Scholar
• Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377–2386.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495–507.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or Adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508–519.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month Phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559–570.
   PubMed Web of Science ®Google Scholar
• Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159(4):253–261.
   PubMed Web of Science ®Google Scholar
• Abboud G, Choi SC, Kanda N, Zeumer-Spataro L, Roopenian DC, Morel L. Inhibition of glycolysis reduces disease severity in an autoimmune model of rheumatoid arthritis. Front Immunol. 2018;9:1973.
   PubMed Web of Science ®Google Scholar
• Raez LE, Papadopoulos K, Ricart AD, et al. A Phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;71(2):523–530.
   PubMed Web of Science ®Google Scholar
• Singh D, Banerji AK, Dwarakanath BS, et al. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol. 2005;181(8):507–514.
   PubMed Web of Science ®Google Scholar
• Wang T, Jiao Y, Zhang X. Immunometabolic pathways and its therapeutic implication in autoimmune diseases. Clin Rev Allergy Immunol. 2021;60(1):55–67.
   PubMedGoogle Scholar
• Badshah H, Ali T, Shafiq-ur R, et al. Protective effect of lupeol against lipopolysaccharide-induced neuroinflammation via the p38/c-Jun N-terminal kinase pathway in the adult mouse brain. J Neuroimmune Pharmacol. 2016;11(1):48–60.
   PubMed Web of Science ®Google Scholar
• Papi Reddy K, Singh AB, Puri A, Srivastava AK, Narender T. Synthesis of novel triterpenoid (lupeol) derivatives and their in vivo antihyperglycemic and antidyslipidemic activity. Bioorg Med Chem Lett. 2009;19(15):4463–4466.
   PubMedGoogle Scholar
• Beattie JH, Nicol F, Gordon MJ, et al. Ginger phytochemicals mitigate the obesogenic effects of a high-fat diet in mice: a proteomic and biomarker network analysis. Mol Nutr Food Res. 2011;55(Suppl 2):S203–213.
   PubMedGoogle Scholar
• Hu YH, Han J, Wang L, et al. alpha-mangostin alleviated inflammation in rats with adjuvant-induced arthritis by disrupting adipocytes-mediated metabolism-immune feedback. Front Pharmacol. 2021;12:692806.
   PubMed Web of Science ®Google Scholar
• Jiang TT, Ji CF, Cheng XP, et al. alpha-mangostin alleviated HIF-1alpha-mediated angiogenesis in rats with adjuvant-induced arthritis by suppressing aerobic glycolysis. Front Pharmacol. 2021;12:785586.
   PubMedGoogle Scholar
• Zuo J, Wang X, Liu Y, et al. Integrating network pharmacology and metabolomics study on anti-rheumatic mechanisms and antagonistic effects against methotrexate-induced toxicity of Qing-Luo-Yin. Front Pharmacol. 2018;9:1.
   PubMedGoogle Scholar
• Byun SH, Lee JH, Jung NC, et al. Rosiglitazone-mediated dendritic cells ameliorate collagen-induced arthritis in mice. Biochem Pharmacol. 2016;115:85–93.
   PubMedGoogle Scholar